38.54
+0.67(+1.77%)
Currency In USD
| Previous Close | 37.87 |
| Open | 37.99 |
| Day High | 38.82 |
| Day Low | 37.51 |
| 52-Week High | 63.5 |
| 52-Week Low | 26.2 |
| Volume | 336,614 |
| Average Volume | 831,258 |
| Market Cap | 2.26B |
| PE | -9.31 |
| EPS | -4.14 |
| Moving Average 50 Days | 38.59 |
| Moving Average 200 Days | 39.57 |
| Change | 0.67 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $1,815.36 as of September 08, 2025 at a share price of $38.54. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $811.2 as of September 08, 2025 at a share price of $38.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on T
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Jul 07, 2025 10:00 AM GMT
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
GlobeNewswire Inc.
Jul 06, 2025 10:00 PM GMT
Webcast to be held Monday, July 7th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differ